Fig. 7.

Simulated weekly dengue incidence incorporating immune-mediated interactions between DENV and ZIKV. The Zika introduction in 2016 (blue) and dengue epidemic in 2019 (red) are highlighted. Models assume ZIKV infection boosts immune groups and either A. moves naïve individuals to the ${\text{R}}_{\text{L}}$ compartment or B. does not. All the parameters used here are in Table S1. Additionally, we estimated parameters associated with the Zika effect from our cohort described above. We report the proportion of individuals who were infected with ZIKV in 2016 (infection probability following ZIKV exposure, $d=0.4$) and following ZIKV infection, the proportion of naïve, $S_1$, lower immune group ${,R}_L$ and intermediate immune group, $R_M$ that experienced a ≥4-fold rise in cross-reactive antibodies (boosting) were, $k_1=0.4,k_2=0.7$ and $k_3=0.7$, respectively.